Help me fill in the blanks of the practice of ED Critical Care. In this podcast, we discuss all things related to the crashing, critically ill patient in the Emergency Department. Find the show notes at emcrit.org.
…
continue reading
コンテンツは Dr Neil Love によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Dr Neil Love またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!
Player FMアプリでオフラインにしPlayer FMう!
Hematologic Oncology | Exploring Clinical Investigator Perspectives on the Optimal Management of Multiple Myeloma
Manage episode 295055953 series 1464173
コンテンツは Dr Neil Love によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Dr Neil Love またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Featuring perspectives from Drs Sagar Lonial and Krina K Patel, including the following topics:
- Faculty Presentation — Sagar Lonial, MD
- Diagnosis, risk stratification and role of cytogenetics in multiple myeloma (MM) (0:00)
- ENDURANCE (E1A11): Results of a Phase III trial evaluating KRd (carfilzomib, lenalidomide and dexamethasone) versus Ienalidomide, bortezomib and dexamethasone (RVd) as initial therapy for patients with MM (5:16)
- Findings from Phase III trials evaluating daratumumab-containing front-line regimens for newly diagnosed MM (7:04)
- Emerging results from Phase III studies evaluating elotuzumab and ixazomib as components of induction therapy (8:40)
- Factors to consider in the treatment selection for newly diagnosed versus relapsed disease (10:16)
- Published research with isatuximab and with selinexor for relapsed/refractory MM (12:41)
- Mechanism of action of selinexor; role of KRd and daratumumab for patients with high-risk MM (15:27)
- Case: A man in his early 60s with standard-risk MM receives RVd and daratumumab on the GRIFFIN trial (23:50)
- Faculty Presentation — Krina K Patel, MD, MSc
- Compositional and mechanistic similarities and differences among, efficacy and safety outcomes with and ongoing investigation of various B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy platforms in MM (36:26)
- Efficacy and safety results from studies evaluating belantamab mafodotin alone (DREAMM-2) or in combination with bortezomib/dexamethasone (DREAMM-6) for relapsed/refractory MM (59:51)
- Available data with novel anti-BCMA bispecific T-cell engagers for patients with MM (1:04:01)
- Published efficacy and safety findings with venetoclax for MM; correlation between t(11;14) status and response (1:07:07)
- Activity and safety of next-generation immunomodulatory agents observed in patients with heavily pretreated MM; other novel strategies in clinical development (1:11:27)
- Discussion of Investigator Survey with Dr Lonial and Dr Patel
- Induction and maintenance therapy for newly diagnosed MM (1:16:09)
- Management of relapsed/refractory disease (1:41:48)
- FDA approval of the antibody-drug conjugate belantamab mafodotin and role of BCMA-directed CAR T-cell therapies in MM (1:51:22)
- Future developments and novel investigational approaches in MM (2:07:14)
1344 つのエピソード
Manage episode 295055953 series 1464173
コンテンツは Dr Neil Love によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Dr Neil Love またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Featuring perspectives from Drs Sagar Lonial and Krina K Patel, including the following topics:
- Faculty Presentation — Sagar Lonial, MD
- Diagnosis, risk stratification and role of cytogenetics in multiple myeloma (MM) (0:00)
- ENDURANCE (E1A11): Results of a Phase III trial evaluating KRd (carfilzomib, lenalidomide and dexamethasone) versus Ienalidomide, bortezomib and dexamethasone (RVd) as initial therapy for patients with MM (5:16)
- Findings from Phase III trials evaluating daratumumab-containing front-line regimens for newly diagnosed MM (7:04)
- Emerging results from Phase III studies evaluating elotuzumab and ixazomib as components of induction therapy (8:40)
- Factors to consider in the treatment selection for newly diagnosed versus relapsed disease (10:16)
- Published research with isatuximab and with selinexor for relapsed/refractory MM (12:41)
- Mechanism of action of selinexor; role of KRd and daratumumab for patients with high-risk MM (15:27)
- Case: A man in his early 60s with standard-risk MM receives RVd and daratumumab on the GRIFFIN trial (23:50)
- Faculty Presentation — Krina K Patel, MD, MSc
- Compositional and mechanistic similarities and differences among, efficacy and safety outcomes with and ongoing investigation of various B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy platforms in MM (36:26)
- Efficacy and safety results from studies evaluating belantamab mafodotin alone (DREAMM-2) or in combination with bortezomib/dexamethasone (DREAMM-6) for relapsed/refractory MM (59:51)
- Available data with novel anti-BCMA bispecific T-cell engagers for patients with MM (1:04:01)
- Published efficacy and safety findings with venetoclax for MM; correlation between t(11;14) status and response (1:07:07)
- Activity and safety of next-generation immunomodulatory agents observed in patients with heavily pretreated MM; other novel strategies in clinical development (1:11:27)
- Discussion of Investigator Survey with Dr Lonial and Dr Patel
- Induction and maintenance therapy for newly diagnosed MM (1:16:09)
- Management of relapsed/refractory disease (1:41:48)
- FDA approval of the antibody-drug conjugate belantamab mafodotin and role of BCMA-directed CAR T-cell therapies in MM (1:51:22)
- Future developments and novel investigational approaches in MM (2:07:14)
1344 つのエピソード
すべてのエピソード
×プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。